Top

International Journal of Clinical Oncology

Published in:

01-10-2015 | Original Article

Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma

Authors: Seiji Asai, Tetsuya Fukumoto, Nozomu Tanji, Noriyoshi Miura, Masao Miyagawa, Kenichi Nishimura, Yutaka Yanagihara, Akitomi Shirato, Yuki Miyauchi, Tadahiko Kikugawa, Masayoshi Yokoyama

Published in: International Journal of Clinical Oncology | Issue 5/2015

Abstract

Background

The purpose of this study was to assess the ability of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to detect upper urinary tract urothelial carcinomas (UTUC) compared with pathological examination of tissues obtained by ureteroscopic biopsy and split cytologic analysis of urine obtained after retrograde pyelography.

Methods

Clinicopathological records of patients at our institution were retrospectively reviewed. Fifty patients with clinically suspected UTUC, who were histologically diagnosed by nephroureterectomy, partial ureterectomy, or endoscopic biopsy, were included. The patient cohort included 42 men and 8 women, with a median age of 73 (range 54–92) years.

Results

Only 27 % of 49 patients with UTUC had positive voided urine cytology, and 33 % of 40 patients had positive split urine cytology. In addition, 40 % of 10 patients had a positive endoscopic biopsy. However, 83 % of 48 patients with UTUC had positive results from FDG-PET/CT examination. The positive predictive value of FDG-PET/CT was 95 %. There were no correlations between sensitivity and tumor stage or tumor grade. Sensitivity of FDG-PET/CT for patients with and without diabetes mellitus was 60 and 89 %, respectively.

Conclusions

These preliminary results from a small number of patients revealed that FDG-PET/CT enabled effective detection of UTUC.

Rouprêt M, Babjuk M, Compérat E et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63:1059–1071CrossRefPubMed

Japanese Association of Cancer Registries, Japan. http://www.jacr.info/publicication/pub_m_12.html. Accessed Aug 2014

Takao A, Saika T, Uehara S et al (2010) Indications for ureteropyeloscopy based on radiographic findings and urine cytology in detection of upper urinary tract carcinoma. Jpn J Clin Oncol 40:1087–1091CrossRefPubMed

Messer J, Shariat SF, Brien JC et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701–705PubMed

Tavora F, Fajardo DA, Lee TK et al (2009) Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol 33:1540–1546CrossRefPubMed

Smith AK, Stephenson AJ, Lane BR et al (2011) Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 78:82–86CrossRefPubMed

Von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405–422CrossRef

Anjos DA, Etchebehere EC, Ramos CD et al (2007) 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48:764–770CrossRefPubMed

Koyama K, Okamura T, Kawabe J et al (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353–358PubMed

10.

Kosuda S, Kison PV, Greenough R et al (1997) Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 24:615–620PubMed

11.

Japanese Urological Association and the Japanese Pathological Society (2002) General rule for clinical and pathological studies on renal pelvic and ureteral cancer, 2nd edn. Kanehara Publishing Co., Tokyo, pp 38–52 (in Japanese)

12.

Potts SA, Thomas PA, Cohen MB et al (1997) Diagnostic accuracy and key cytologic features of high-grade transitional cell carcinoma in the upper urinary tract. Mod Pathol 10:657–662PubMed

13.

Skolarikos A, Griffiths TR, Powell PH et al (2003) Cytologic analysis of ureteral washing is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology 61:1146–1150CrossRefPubMed

14.

Ceriani L, Suriano S, Ruberto T et al (2011) Could different hydration protocols affect the quality of 18F-FDG PET/CT images? J Nucl Med Technol 39:77–82CrossRefPubMed

15.

Yeh CL, Chen SW, Chen YK (2009) Delayed diuretic FDG PET/CT scan facilitates detection of renal urothelial cell carcinoma. Clin Nucl Med 34:829–830CrossRefPubMed

16.

Crippa F, Gavazzi C, Bozzetti F et al (1997) The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 83:748–752PubMed

17.

Lindholm P, Minn H, Leskinen-Kallio S et al (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6PubMed

18.

Delbeke D, Coleman RE, Guiberteau MJ et al (2006) Society of nuclear medicine (SNM): procedure guideline for SPECT/CT imaging 1.0. J Nucl Med 47:1227–1234PubMed

19.

Hara T, Higashi T, Nakamoto Y et al (2009) Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging? Ann Nucl Med 23:657–669CrossRefPubMed

20.

Busing KA, Schonberg SO, Brade J et al (2013) Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET/CT. Nucl Med Biol 40:206–213CrossRefPubMed

Title: Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma
Authors: Seiji Asai
Tetsuya Fukumoto
Nozomu Tanji
Noriyoshi Miura
Masao Miyagawa
Kenichi Nishimura
Yutaka Yanagihara
Akitomi Shirato
Yuki Miyauchi
Tadahiko Kikugawa
Masayoshi Yokoyama
Publication date: 01-10-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0817-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2015

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study

Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis

ISRT: a new radiation therapy for malignant lymphomas

Patterns of metastasis from the primary site to the testes indicate the potential pathway of metastasis

How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer